TY  - JOUR
TI  - Development of Hypocalcemia Due to Targeted Therapies
AB  - Novel biological agents are available for the treatment of malignancies, and apart from their utility, they may also have several side effects. The effects on the endocrine system are frequently observed, among which thyroid dysfunctions are common and well-characterized, whereas parathyroid dysfunctions are rare and not well characterized. Herein, we describe two of our patients that displayed hypoparathyroidism and were treated with epidermal growth factor receptor (EGFR) inhibitor erlotinib, vascular endothelial growth factor receptor, and EGFR inhibitor vandetanib.
AU  - ERDOĞAN, MURAT FAİK
AU  - AYDOĞAN, Berna İmge
AU  - GÖKÇAY CANPOLAT, Asena
AU  - GULLU, SEVIM
AU  - CANLAR, Sule
DO  - 10.25179/tjem.2019-70737
PY  - 2020
JO  - Turkish Journal of Endocrinology and Metabolism
VL  - 24
IS  - 1
SN  - 1301-2193
SP  - 105
EP  - 108
DB  - TRDizin
UR  - http://search/yayin/detay/340668
ER  -